JP2023540795A5 - - Google Patents
Info
- Publication number
- JP2023540795A5 JP2023540795A5 JP2023516052A JP2023516052A JP2023540795A5 JP 2023540795 A5 JP2023540795 A5 JP 2023540795A5 JP 2023516052 A JP2023516052 A JP 2023516052A JP 2023516052 A JP2023516052 A JP 2023516052A JP 2023540795 A5 JP2023540795 A5 JP 2023540795A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- pharmaceutical composition
- treatment
- composition according
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078211P | 2020-09-14 | 2020-09-14 | |
| US63/078,211 | 2020-09-14 | ||
| US202063106302P | 2020-10-27 | 2020-10-27 | |
| US63/106,302 | 2020-10-27 | ||
| US202163185357P | 2021-05-06 | 2021-05-06 | |
| US63/185,357 | 2021-05-06 | ||
| PCT/IB2021/058229 WO2022053990A1 (en) | 2020-09-14 | 2021-09-10 | Methods, therapies and uses for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023540795A JP2023540795A (ja) | 2023-09-26 |
| JP2023540795A5 true JP2023540795A5 (enExample) | 2024-09-17 |
Family
ID=77989848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516052A Pending JP2023540795A (ja) | 2020-09-14 | 2021-09-10 | がんを処置するための方法、治療、および使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230340137A1 (enExample) |
| EP (1) | EP4211167A1 (enExample) |
| JP (1) | JP2023540795A (enExample) |
| KR (1) | KR20230069181A (enExample) |
| CN (1) | CN116194105A (enExample) |
| AU (2) | AU2021339096B2 (enExample) |
| BR (1) | BR112023003688A2 (enExample) |
| CA (1) | CA3194925A1 (enExample) |
| IL (1) | IL300884A (enExample) |
| MX (1) | MX2023003034A (enExample) |
| TW (1) | TWI914401B (enExample) |
| WO (1) | WO2022053990A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025540215A (ja) * | 2022-12-09 | 2025-12-11 | ファイザー・インク | Ｃｄ４７遮断剤と抗ｂｃｍａ／抗ｃｄ３二重特異性抗体との組合せ療法 |
| WO2024263845A1 (en) * | 2023-06-22 | 2024-12-26 | Genentech, Inc. | Treatment of multiple myeloma |
| TW202523350A (zh) | 2023-08-10 | 2025-06-16 | 美商輝瑞股份有限公司 | 治療癌症之方法，療法及用途 |
| WO2025096717A1 (en) * | 2023-11-01 | 2025-05-08 | Janssen Biotech, Inc. | Methods for treating multiple myeloma |
| WO2025122813A1 (en) * | 2023-12-08 | 2025-06-12 | Board Of Regents, The University Of Texas System | Protecting cell therapies from tgf-beta induced immunosuppression |
| TW202532072A (zh) * | 2023-12-08 | 2025-08-16 | 美商西建公司 | 治療多發性骨髓瘤之療法 |
| WO2026059920A1 (en) * | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with pd1/pd-l1 inhibitors |
| WO2026072671A1 (en) | 2024-09-24 | 2026-04-02 | City Of Hope | Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP1135415B1 (en) | 1998-12-01 | 2010-08-11 | Facet Biotech Corporation | Humanized antibodies to gamma-interferon |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| ATE399155T1 (de) | 2004-03-23 | 2008-07-15 | Pfizer Prod Inc | Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen |
| KR101577843B1 (ko) | 2007-12-14 | 2015-12-16 | 브리스톨-마이어스 스큅 컴퍼니 | 인간 ｏｘ４０ 수용체에 대한 결합 분자 |
| SG10201912092VA (en) | 2010-09-09 | 2020-02-27 | Pfizer | 4-1bb binding molecules |
| SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
| TWI589592B (zh) | 2011-11-17 | 2017-07-01 | 輝瑞股份有限公司 | 胞毒性肽類以及其抗體藥物共軛體 |
| KR20170010863A (ko) | 2014-07-01 | 2017-02-01 | 화이자 인코포레이티드 | 이중특이성 이종이량체성 디아바디 및 이의 용도 |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| IL310723A (en) * | 2015-04-13 | 2024-04-01 | Pfizer | Therapeutic antibodies and their uses |
| WO2017031104A1 (en) * | 2015-08-17 | 2017-02-23 | Janssen Pharmaceutica Nv | Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof |
| AU2016368469B2 (en) * | 2015-12-09 | 2023-11-02 | F. Hoffmann-La Roche Ag | Type II anti-CD20 antibody for reducing formation of anti-drug antibodies |
| EP3535295A1 (en) * | 2016-11-02 | 2019-09-11 | EngMab Sàrl | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
| US20200179511A1 (en) * | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| KR20250036941A (ko) | 2017-05-31 | 2025-03-14 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도 |
| PE20242042A1 (es) | 2017-06-02 | 2024-10-10 | Pfizer | Anticuerpos especificos para flt3 y sus usos |
| TWI838389B (zh) * | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| EP3830122A1 (en) * | 2018-07-31 | 2021-06-09 | Amgen Research (Munich) GmbH | Dosing regimen for bcma-cd3 bispecific antibodies |
| PT3844189T (pt) * | 2018-08-31 | 2025-01-29 | Regeneron Pharma | Estratégia de dosagem que mitiga a síndrome de libertação de citocinas para anticorpos bisepecíficos contra cd3/c20 |
| US20220003772A1 (en) * | 2018-10-31 | 2022-01-06 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
| CA3182887A1 (en) * | 2020-05-13 | 2021-11-18 | Pfizer Inc. | Methods, therapies and uses for treating cancer |
-
2021
- 2021-09-10 CN CN202180062823.5A patent/CN116194105A/zh active Pending
- 2021-09-10 CA CA3194925A patent/CA3194925A1/en active Pending
- 2021-09-10 EP EP21782599.1A patent/EP4211167A1/en active Pending
- 2021-09-10 US US18/025,879 patent/US20230340137A1/en active Pending
- 2021-09-10 TW TW110133770A patent/TWI914401B/zh active
- 2021-09-10 MX MX2023003034A patent/MX2023003034A/es unknown
- 2021-09-10 JP JP2023516052A patent/JP2023540795A/ja active Pending
- 2021-09-10 WO PCT/IB2021/058229 patent/WO2022053990A1/en not_active Ceased
- 2021-09-10 AU AU2021339096A patent/AU2021339096B2/en active Active
- 2021-09-10 IL IL300884A patent/IL300884A/en unknown
- 2021-09-10 BR BR112023003688A patent/BR112023003688A2/pt unknown
- 2021-09-10 KR KR1020237012640A patent/KR20230069181A/ko active Pending
-
2026
- 2026-03-11 AU AU2026201847A patent/AU2026201847A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018506550A5 (enExample) | ||
| JP2017523187A5 (enExample) | ||
| JP2019517549A5 (enExample) | ||
| JP2018184417A5 (enExample) | ||
| JP2021517566A5 (enExample) | ||
| JP2019521988A5 (enExample) | ||
| JP2023501375A5 (enExample) | ||
| JP2020500181A5 (enExample) | ||
| JP2025185043A (ja) | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 | |
| JP2015500822A5 (enExample) | ||
| JP2015525798A5 (enExample) | ||
| JP2014511383A5 (enExample) | ||
| JP2019501886A5 (enExample) | ||
| JP2018530578A5 (enExample) | ||
| JP2015517511A5 (enExample) | ||
| RU2014127298A (ru) | Применения иммуноконъюгатов, мишенью которых является cd138 | |
| RU2018107693A (ru) | Комбинированные виды лечения и их варианты применения и способы | |
| RU2017128616A (ru) | Комбинированное лекарственное средство | |
| JP2015172060A5 (enExample) | ||
| JP2017537927A5 (enExample) | ||
| RU2020134307A (ru) | Режимы дозирования мелфлуфена для раковых заболеваний | |
| JP2020158544A5 (enExample) | ||
| JP2025515092A5 (enExample) | ||
| JP2019519584A5 (enExample) | ||
| JP2021506817A5 (enExample) |